In inflammatory autoimmune disease such as Inflammatory Bowels diseases (IBD) Rheumatoid Arthritis (RA), Multiple Sclerosis (MS) and others the activity of effector autoimmune T cells is tightly regulated by FOXp3+ regulatory T cells (Tregs). CCL1 is a chemokine with a very short half-life time (in vivo) that exclusively potentiates the activity of these cells. We have generated a CCL1-Ig based fusion protein (also referred to as CCL1-Fc) with a substantially longer half-life in vivo (PK) and a very long in vivo activity (PD) that function as an agonistic molecule for FOXP3+ Tregs and effectively suppresses ongoing autoimmunity.
- Effectively treats different autoimmune diseases in experimental models (EAE, IBD)
- As an agonistic molecule, has a long half life time
- Likely to have low toxicity
- Robust in vitro and ex-vivo assays relevant to the MOA of the drug.
Applications and Opportunities
- Autoimmunity, chronic inflammation
Business Development Contacts
Dr. Gal Gur
Director of Business Development, Life Sciences